NASDAQ · NMRA
Healthcare · Biotechnology
$0.37
Down-$0.02 (-5.43%)
Updated Nov 1, 2026, 9:17 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NMRA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
NMRA closed at $0.37 after 20 trading sessions, down 30.10% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $0.4068 | $0.4097 | $0.3523 | $0.3672 | 1.11M |
| Oct 29, 2026 | $0.3968 | $0.41 | $0.3677 | $0.3883 | 1.38M |
| Oct 28, 2026 | $0.3655 | $0.3957 | $0.361 | $0.3931 | 1.12M |
| Oct 27, 2026 | $0.3885 | $0.4206 | $0.3612 | $0.3681 | 1.74M |
| Oct 26, 2026 | $0.3874 | $0.43 | $0.3737 | $0.3929 | 512.16K |
| Oct 23, 2026 | $0.3986 | $0.414 | $0.3658 | $0.3794 | 835.86K |
| Oct 22, 2026 | $0.43 | $0.435 | $0.3873 | $0.4057 | 865.07K |
| Oct 21, 2026 | $0.47 | $0.4762 | $0.4057 | $0.416 | 1.58M |
| Oct 20, 2026 | $0.48 | $0.4963 | $0.4574 | $0.465 | 974.53K |
| Oct 19, 2026 | $0.4684 | $0.5049 | $0.4602 | $0.47 | 1.65M |
| Oct 16, 2026 | $0.4366 | $0.5062 | $0.42 | $0.4738 | 3.52M |
| Oct 15, 2026 | $0.365 | $0.4595 | $0.3601 | $0.427 | 6.46M |
| Oct 14, 2026 | $0.39 | $0.40 | $0.3154 | $0.3545 | 2.8M |
| Oct 13, 2026 | $0.43 | $0.4353 | $0.3668 | $0.3702 | 1.5M |
| Oct 12, 2026 | $0.4815 | $0.4815 | $0.4355 | $0.4373 | 1.21M |
| Oct 9, 2026 | $0.4701 | $0.51 | $0.47 | $0.4757 | 789.43K |
| Oct 8, 2026 | $0.4634 | $0.4869 | $0.4504 | $0.4798 | 1.81M |
| Oct 7, 2026 | $0.4647 | $0.4819 | $0.4514 | $0.4683 | 2.76M |
| Oct 6, 2026 | $0.5253 | $0.539 | $0.47 | $0.471 | 1.23M |
| Oct 5, 2026 | $0.50 | $0.5336 | $0.4717 | $0.5253 | 2.99M |
The latest Smart Investors Daily articles mentioning NMRA.
Company
Market Activity
Research & News
NMRA research
Company profile and research snapshot.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | RBC Capital | Outperform | — |
| Jun 18, 2026 | Mizuho | Outperform | — |
| Jun 16, 2026 | Needham | Buy | — |
| Jun 16, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 31, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 15, 2026
Gainers Regencell Bioscience (NASDAQ:RGC) stock increased by 30.4% to $10.58 during Thursday's regular session. The company's market cap stands at $4.0 billion. SenesTech (NASDAQ:SNES) stock rose 24.93% to
Yahoo · Sep 18, 2026
UTHR, NMRA, and EWTX are drawing attention from options bears
Yahoo · Sep 4, 2026
ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthusamy (Samy) Shanmugam resigned from the Board and will continue in key operational roles at ANI Pharmaceuticals. This kind of board refresh is not unique to ANI Pharmaceuticals, and investors who want broader exposure to companies shaped closely by their...
Benzinga · Aug 14, 2026
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 30.3 percent increase over losses of $(0.33) per share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NMRA.
